Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report

Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wherrett, Diane K., Chiang, Jane L., Delamater, Alan M., DiMeglio, Linda A., Gitelman, Stephen E., Gottlieb, Peter A., Herold, Kevan C., Lovell, Daniel J., Orchard, Trevor J., Ryan, Christopher M., Schatz, Desmond A., Wendler, David S., Greenbaum, Carla J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2015
Materias:
Consensus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876737/
https://www.ncbi.nlm.nih.gov/pubmed/26404927
http://dx.doi.org/10.2337/dc15-1429
Descripción
Sumario:Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes–modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.

Ejemplares similares